VIENNA, Va. — CEL-SCI Corp. and its scientific collaborators announced Feb. 22 that the company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis in a mouse model.
The results were published in the scientific peer-reviewed Journal of International Immunopharmacology (online edition) in an article with lead author Dr. Daniel Zimmerman. The study was co-authored by scientists from CEL-SCI, Washington Biotech, Northeastern Ohio Universities Colleges of Medicine and Pharmacy and Boulder BioPath.
CEL-2000, administered after symptoms had started, prevented the further development of arthritic conditions, including joint swelling and deformation, bone and cartilage changes. It was accompanied by serum cytokine alterations during the CEL-2000 treatment period with comparable or better activity than the well-accepted Enbrel therapy. The results were in a statistically significant.
"These experimental results were achieved through a reduction of the inflammatory response that is known to attack the patients' joints,” said Geert Kersten, CEO of CEL-SCI.
The company said its CEL-2000 treatment was deemed safe and well tolerated without any reported adverse effects related to treatment.